Biomea Fusion Inc

Research Biomea Fusion Inc (BMEA) on Bullrun: market cap USD 100.50M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBMEA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 100.50M
• Financial periodFY2025
• Net income-USD 61.80M

Valuation Snapshot

latest market cap is USD 100.50M.

About Biomea Fusion Inc

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes;

Frequently asked questions

What is Biomea Fusion Inc's market cap?

Biomea Fusion Inc's market capitalization is USD 100.50M.

What does Biomea Fusion Inc do?

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity.